India's pharmaceutical retail market is undergoing a behavioral shift as quick-commerce platforms expand their reach into medicine delivery. Data from research firm Pharmarack indicates that total sales remained largely flat, declining to around ₹20,000 crore by March 2026. However, there is a noticeable divergence in brand performance; repeat-use wellness products, such as Centrum Silver and chronic therapies like Glycitop, are experiencing mid-to-high single-digit growth, while several acute-care brands are seeing declines. This trend reflects changing consumer preferences, particularly among younger and health-conscious consumers, as noted by Sujay Shetty, Global Leader of Health Industries at PwC India. The entry of quick-commerce startup Zepto, which launched a 10-minute medicine delivery service in major cities like Delhi-NCR and Mumbai, exemplifies this shift. Despite the potential for growth, the overall market remains flat, indicating that quick-commerce is redistributing demand rather than expanding it. The OTC drug market is projected to grow significantly, but structural constraints and regulatory frameworks limit the speed of transformation. As quick-commerce platforms continue to evolve, they are likely to reshape consumption patterns, particularly in the wellness segment.